MedTrace Logo

Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA

NCT00434213 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 309

Last updated 2017-04-26

Study results available
· View outcomes & findings →

Summary

This is a study designed to characterize the dermal response of DAYTRANA. Subjects will visit the study site over a period of approximately 14 weeks.

Conditions

  • Attention Deficit Hyperactivity Disorder

Interventions

DRUG

Daytrana

Methylphenidate Transdermal System (MTS)

Sponsors & Collaborators

  • Noven Therapeutics

    lead INDUSTRY

Principal Investigators

  • Timothy Wilens, MD · Harvard Medical School (HMS and HSDM)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2007-08-31
Completion
2008-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00434213 on ClinicalTrials.gov